GlassScriptPhysician profile
Sharon Choi
NPI 1376842120
$4,441.48
in general payments reported to CMS, 2019-2025
29 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $248 · 2021: $476 · 2022: $672 · 2023: $956 · 2024: $816 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $764.04 | 2019-2025 | |
| Pfizer INC. | $509.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $455.29 | 2020-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.45 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $374.55 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $307.54 | 2023-2025 | Symplicity G3, Onyx Frontier |
| Amgen INC. | $283.18 | 2019-2025 | Repatha |
| Amarin Pharma, INC. | $273.56 | 2019-2022 | |
| Novo Nordisk INC | $157.75 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $146.59 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $127.35 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $76.28 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.27 | 2022-2025 | Lifevest |
| Innovation Technologies INC | $64.30 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $58.64 | 2021-2023 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $56.43 | 2023 | Glidewire, Metacross Otw, Heartrail |
| Recor Medical INC | $38.80 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Lantheus Medical Imaging, INC. | $37.12 | 2020-2024 | |
| Lexicon Pharmaceuticals, INC. | $34.91 | 2023 | Inpefa |
| Convatec INC. | $28.30 | 2023 | |
| Ethicon US, LLC | $23.47 | 2024 | Vistaseal |
| Boston Scientific Corporation | $20.91 | 2025 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $19.51 | 2024 | Arcalyst |
| Astellas Pharma US INC | $18.22 | 2020 | |
| Tactile Systems Technology INC | $16.68 | 2025 | Flexitouch Plus, Nimbl |
| Cvrx, INC. | $16.17 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.62 | 2021 | |
| Heartflow, INC. | $13.76 | 2022 | |
| Scpharmaceuticals INC. | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.